http://rdf.ncbi.nlm.nih.gov/pubchem/reference/23670347

Outgoing Links

Predicate Object
contentType Journal Article
endingPage 1089
issn 2156-6976
issueIdentifier 6
pageRange 1083-1089
publicationName American journal of cancer research
startingPage 1083
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_e57a2df28cd3d691c9ebea9a73b49d7b
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_199db1bef4b0308c0639203aa0befa4f
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_1d29cec6973140dbd24b84058a325666
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_7b06054cb3290cb2ff62e3b094b84de7
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ae2f46b216619872e52305b0ab237107
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_472a3aab51bdf628eca3973b1b0cc973
bibliographicCitation Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, Yin J, You F, Zhu M, Shen W, Chen G, Zhu X, Wu D, Yu J. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8(6):1083–9. PMID: 30034945; PMCID: PMC6048396.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16e75832cc69a51e801f9adc07c885ce
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d9c9963fdb9639373e26e6cae3762c59
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6889890b5f4956b54dc6f6cc717d17af
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f749cfdca0d90dd1b6d4e4932dc98ecc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9ccc1dfe906350704c895d4d0876b786
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7a269c7da40ca429682d099f729c83d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3dece6a21ea411d4b474215112c1644f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_522c31741d20601dcf2a1e5a23d9681b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ed38994c28473fa316beda9b8e329401
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_34dec25afff7e0a6a1bc2df40af7fbcd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a063901e9a5340ea04bd7d48d58fa9e4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab01ae9bd45a7acdc853e9a0b0641450
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_96cd295850345de164fd6cf8f4ae2488
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b636647f440db9041e42e18e4365d7b
date 2018
identifier https://pubmed.ncbi.nlm.nih.gov/PMC6048396
https://pubmed.ncbi.nlm.nih.gov/30034945
isPartOf https://portal.issn.org/resource/ISSN/2156-6976
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/38854
language English
source https://pubmed.ncbi.nlm.nih.gov/
title First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11043
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9731
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7cae9972de6deccb83ee4f720cac0e7d
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6700

Total number of triples: 43.